If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Directorate Change

14 Dec 2012 07:00

RNS Number : 5188T
Immunodiagnostic Systems Hldgs PLC
14 December 2012
 



14 December 2012

 

Immunodiagnostic Systems Holdings plc

 

Chris Yates appointed as Group Finance Director

 

 

Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of manual and automated specialist diagnostic testing kits and instrumentation for the clinical and research markets, today announces that Chris Yates has been appointed Group Finance Director, with effect from 4th March 2013. 

 

Chris Yates, aged 38, joins IDS from private equity backed Nexus Vehicle Holdings Limited, where he has acted as Group Finance Director since January 2009. During his time at Nexus, as well as holding overall responsibility for finance and human resources, Chris oversaw the acquisition of Adapted Vehicle Hire Limited in May 2010.

 

From 2005 to 2007, Chris held the position of Group Finance Director at Cozart plc, allowing him to gain significant experience in the medical diagnostics industry.  During his time at Cozart, Chris led the acquisitions of four European companies: Spinreact SA (Spain), HL Scandinavia (Sweden), Nemesis Scientific Limited (UK) and Medib Skandinavien AB (Sweden) creating a pan-European medical diagnostics group. Cozart was subsequently acquired by Concateno plc (now part of Alere Inc.) in October 2007 for £64m in cash.

 

In 2008 Chris then furthered his industry expertise by acting as Co-founder and Finance Director of private specialist diagnostics company, Abingdon Health Limited.

 

From 4th March 2013 Barry Hextall, currently interim Group Finance Director, will resume his previous role as Deputy Group Finance Director.

 

Patrik Dahlen, Chief Executive Officer of IDS, commented: "It is a pleasure to announce that Chris Yates will be joining our team as Group Finance Director. As well as having a strong financial background, I am confident that Chris's knowledge and experience in the diagnostics industry will prove to be invaluable to IDS during this crucial time in the evolution of the business as a leading innovator and provider of specialist assays and diagnostic testing kits.

 

"I would also like to thank Barry Hextall for his continued support as Interim Finance Director."

 

For further information:

 

Immunodiagnostic Systems Holdings plc

Tel : +44 (0)191 519 0660

Patrik Dahlen, Chief Executive Officer

 

 

 

 

 

Peel Hunt LLP

Tel : +44 (0)207 418 8900

James Steel

 

Dr Vijay Barathan

 

 

 

FTI Consulting

Tel : +44 (0)207 831 3113

Ben Atwell

 

Simon Conway

 

Mo Noonan

 

 

 

Additional Information

Christopher Henry Francis Yates (aged 38) currently holds and has held (including all appointments during the five years preceding the date of this announcement), the following directorships and partnerships, other than the Company:

 

Current directorships:

Adapted Vehicle Hire Limited

Forsite Diagnostics Limited

Nexus VRM Limited

Nexus Vehicle Management Ltd

Nexus Vehicle Holdings Limited

Abingdon Health LTD

 

Chris currently has no shares in the Company and there are no other disclosures required pursuant to Rule 17 and Schedule 2; paragraph (g) of the AIM Rules for Companies.

 

About Immunodiagnostic Systems Holdings PLC

The Group operates in the in-vitro diagnostics ("IVD") market by designing, manufacturing and selling immunoassay kits as well as its automated analyser, the IDS-iSYS System. The IDS product range is used to measure or detect particular substances within a sample, thus aiding the diagnosis or monitoring of a disease or providing information for research studies.

 

http://www.idsplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGGGQGPUPPPWW
Date   Source Headline
27th Oct 20174:23 pmRNSTransaction in Own Shares
23rd Oct 20175:38 pmRNSTransaction in Own Shares
20th Oct 20174:30 pmRNSH1 Trading Update
5th Oct 20179:49 amRNSHolding(s) in Company
5th Oct 20179:42 amRNSHolding(s) in Company
5th Oct 20179:39 amRNSHolding(s) in Company
2nd Oct 20176:08 pmRNSHolding(s) in Company
22nd Sep 20177:25 amRNSTransaction in Own Shares
20th Sep 20176:09 pmRNSTransaction in Own Shares
18th Sep 20173:23 pmRNSTransaction in Own Shares
10th Aug 20172:00 pmRNSLaunch of IDS-iSYS
10th Aug 20178:37 amRNSTransaction in Own Shares
9th Aug 20177:00 amRNSTransaction in Own Shares
2nd Aug 20179:30 amRNSDirector/PDMR Shareholding
2nd Aug 20178:33 amRNSHolding(s) in Company
2nd Aug 20178:30 amRNSHolding(s) in Company
27th Jul 20173:45 pmRNSResult of AGM
27th Jul 20178:00 amRNSTransaction in Own Shares
27th Jul 20177:00 amRNSAGM Statement
24th Jul 20177:00 amRNSTransaction in Own Shares
3rd Jul 20174:12 pmRNSDirector/PDMR Shareholding
28th Jun 20178:28 amRNSDirector/PDMR Shareholding
22nd Jun 20175:33 pmRNSDirector/PDMR Shareholding
21st Jun 20177:30 amRNSPublication of Annual Report and Accounts
21st Jun 20177:01 amRNSShare Buyback Programme
21st Jun 20177:00 amRNSFinal Results
21st Apr 20177:00 amRNSTrading Update
23rd Mar 20179:14 amRNSDirector/PDMR Shareholding
13th Mar 20178:31 amRNSDirectorate Change
1st Mar 201710:01 amRNSLaunch of IDS-iSYS InaKtif MGP assay
24th Feb 20173:31 pmRNSUpdate on CEO Appointment
7th Feb 20172:46 pmRNSHolding(s) in Company
2nd Feb 20173:14 pmRNSLaunch of IDS-iSYS ACTH assay
26th Jan 20173:05 pmRNSHolding(s) in Company
20th Jan 20174:24 pmRNSDirector Dealing
20th Jan 201710:30 amRNSHolding(s) in Company
19th Jan 20171:12 pmRNSDirectorate Change
18th Jan 201712:26 pmRNSHolding(s) in Company
11th Jan 20173:14 pmRNSDirector/PDMR Shareholding
5th Jan 20175:35 pmRNSHolding(s) in Company
5th Jan 20174:38 pmRNSHolding(s) in Company
25th Nov 20168:00 amRNSHalf-year Report
21st Oct 20167:00 amRNSH1 Trading Update
19th Oct 20167:00 amRNSLaunch of IDS-iSYS Total Testosterone assay
28th Jul 20163:18 pmRNSResult of AGM
28th Jul 20167:00 amRNSAGM Statement
11th Jul 201611:46 amRNSDirector/PDMR Shareholding
5th Jul 201610:07 amRNSDirector/PDMR Shareholding
30th Jun 20166:15 pmRNSDirector/PDMR Shareholding
28th Jun 20166:13 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.